Akari Therapeutics Plc
For the period ended Sep 30, 2024. Filed Nov 19, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 19, 2024
AKTX$7.13-6.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
Condensed Consolidated Statements of Operations
and Comprehensive Loss
| Three Months Ended · Nine Months Ended | ||||
|---|---|---|---|---|
| September 30, | September 30, | |||
| (In thousands, except share and per share amounts) | 2024 | 2023 | 2024 | 2023 |
| Operating expenses: | ||||
| Research and development | $143 | $(314) | $5,736 | $2,941 |
| General and administrative | 1,709 | 2,821 | 6,616 | 8,775 |
| Merger-related costs | 992 | — | 2,290 | — |
| Restructuring and other costs | 83 | — | 1,723 | — |
| Loss from operations | (2,927) | (2,507) | (16,365) | (11,716) |
| Other income (expense): | ||||
| Interest income | 3 | 16 | 7 | 75 |
| Interest expense | (69) | — | (120) | — |
| Change in fair value of warrant liability | 30 | (258) | 528 | 5,889 |
| Foreign currency exchange gain (loss), net | 68 | (100) | (67) | (72) |
| Other expense, net | — | (22) | (2) | (46) |
| Total other income (expense), net | 32 | (364) | 346 | 5,846 |
| Net loss | $(2,895) | $(2,871) | $(16,019) | $(5,870) |
| Net loss per share –– basic and diluted | $(0.00) | $(0.00) | $(0.00) | $(0.00) |
| Weighted-average number of ordinary shares used in computing net loss per share –– basic and diluted | 24,386,005,523 | 10,116,903,598 | 18,911,928,794 | 10,119,421,200 |
| Comprehensive loss: | ||||
| Net loss | $(2,895) | $(2,871) | $(16,019) | $(5,870) |
| Other comprehensive income, net of tax: | ||||
| Foreign currency translation adjustment | (177) | (3) | 114 | (58) |
| Total other comprehensive income, net of tax | (177) | (3) | 114 | (58) |
| Total comprehensive loss | $(3,072) | $(2,874) | $(15,905) | $(5,928) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.